HUE032403T2 - Bicikloanilin származék - Google Patents

Bicikloanilin származék Download PDF

Info

Publication number
HUE032403T2
HUE032403T2 HUE08777358A HUE08777358A HUE032403T2 HU E032403 T2 HUE032403 T2 HU E032403T2 HU E08777358 A HUE08777358 A HU E08777358A HU E08777358 A HUE08777358 A HU E08777358A HU E032403 T2 HUE032403 T2 HU E032403T2
Authority
HU
Hungary
Prior art keywords
group
production
compound
added
production example
Prior art date
Application number
HUE08777358A
Other languages
English (en)
Inventor
Makoto Bamba
Hidetomo Furuyama
Kenji Niiyama
Toshihiro Sakamoto
Satoshi Sunami
Keiji Takahashi
Fuyuki Yamamoto
Takashi Yoshizumi
Original Assignee
Msd Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Kk filed Critical Msd Kk
Publication of HUE032403T2 publication Critical patent/HUE032403T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (3)

  1. Skabiglälftti iftéttypontek I. ÁHsIIms !:<-pfos:« tI) vegytifet-
    píol: A- 4s -V' enmkgysk főggekenö! .eRiSypts etsesskyvegy Sstefe esàptRRR.j:síísíí&amp;íÍV <^>ώ:ϊϊ>ίϊΞΪΐΐΗ^:ίϊ xytkeenteiit wt vas $ssktg&amp;s atötRíkék RkisMili .gssgkMiak, elásó gSpipRRälK €%;*(£&amp; âtkiiéSégkétsal:. b i k síkost sepora»; wsgy hiikM k Ç i ·0> äSMi ckppsptiéi; B gyűrű. annűv kgpkS: (s) seenak pykniV:?l vmböísáeéktiv a:
    I ** amely ki sass vlkRaiSit kepSeíN-R ;k h aH-> regxethk
    IMI Mpiek>ú| k:;-2) Ilié eseptaiMk
    [Mi vagy kepkríhö; (b-J) ;ik6 sxí-penbűi:
    ( b«3 1 ahv? rgy vMy kettő vagy egek stótiBe tkögerk amely etünk R tsíkeifísk, ílgeetieppl lx·: s > -í ? s i· η ? t n í : s< · k esi gets stgmsytak kepMampaL MalíMt eseptapak sealtPeO: rsoperoai kasbopik esppRÍ'ítki vagy NÍR’V <\op:'et:;S!; gs egy ypgp kettő vagy kék; me-ike esppórk tanviyek gytRöí it Jk' Vi x V vK ! î\ »! » ο- ' 'S>1 ^ ‘ ^ *,v- ' *' x > I;ui;<sxi-Cs C6 islkiî c/npnsí«t'i vagy ·|!>··Ν(ΐΙ|Βΐ »χορ^'Οΐ ly ani vAgy !w<ewe»kiiko* cxsponot »dem.. npcb»^* »«»feaatrtw&amp;lva halogén smmmalva|r Cl·Όδ älkü csopontal: »-C o*'. ^ C »muRgMk Riggvtkmk ''^v 's ^ u * ;iïk!Î''i! v-» λ a«x 1 - Ngv U' Ο \ *>:- »ot»h \»»k '<.<"<« ' ' v * * * ^ '' vN ’R"* ' X î ^ Bíg^-kk-nas -»- -mx-kho-ox vaCsu ϊ'ν,<:\" Η -/ ^ s-jS'sws '-jJ- - Il hùki^m «cmu jeket xapg Cl-Ch alle«! eux»** &amp;<**> «»*<y«k ope***!*» va, •-/'.hx/UäXK'axc, aiïK'ly S·:', -ss v à sásaivá s kôx.gikfi'Xî^kîli ask> xxnpxs'Oxd: hak'gen 3K;«:>, ηκήοχη elásó csoport, Ct-O'î dkwô esyx-n. Ca-CP otk.íoaíksí csapon, f- '' alkam?»? ηχ-ηχη» v-s ^ 4 -ζ·-? .Ckik/nHnnn -.«'port -agy snk mdksi - ay y kvieixmos e.^pof» ot jCom, anvv-xek openmao'-m '-JO ‘»sasbsv'.o(sea».»·, astdy k; van vàîaxisrva a klkdka/ôkikd a06 vxopoobo]. îsa.CgÇs ssï'.xn. p«h->xO -..\opwt, elásó osoporl, aisiso evaporî, CIO» aîkiS eaopos'l, C : -CP ïd*-;y,o c:&amp;»porh !»a»»»-< »s< n»s 0 »χοροί-*..-hkkoxCCI-CS cdkîi csoport; esnponoi jsle/iK «^^t^^k^feswt^-aasásx^ns^ «msir M vsB vliassava a klwdkex&amp;te&amp;! allé smpsnbé!: kdogso atom. hídh>»d »;»*>ροπ. >'iano csoport. w*' csoport, CI-CP îtïlcïl csoposC CI-C6 afem csoport, Cak'-C f -Ce s>KH esopots: es kídtokl-'C 0-0¾ PsPts csopotl: X * hí 1*0». " -»k ':''' 0 VOt -'p,- í. S X. -- ilk'k ',' > Ct- OjkkXílk.i 'Sg'v > ?-* o.iL-Uí'i. CsOj-OkOt ». '; ív . mch x .- --*χ X nau»ao -.«s soR-* ; Ηχον., amch K· -an \-èvins a Vos étke .vklx-] all-' v\epo»1ív! kdogói» atotn, hkirodí osoposy csaso csoport,· C1-C6 slkoxvcsopott, Ca-CP oikiöslkk csoport .*·.» *...>·.··Ι ·' àlUS-i! csop.Mt. '-ng- <}'''-i g -·η gyO !à N ; H! y R! “ CK, >;V<!i ni ,r k í 0:. l|K é/ R! niííKÍapylí·' nfggiXkr.ü! iridTogía aíoínat jeimk vagy (. !-(.<> alks», \ ,2-k íí!xs».»'.x· v»»g> < - » ^<»\ » î '«»I V X >o -i'( vík '-'X- j\ -, »< l-4* in'- '< íf - -ív ΐΓ > k* V - '1 ' ' jköYetkVi&amp;kbäi átló ». sittből: k&amp;kígén ats)sn hkirostl o^porl. daxo » sopnrs. Os-Ct- alkóv» csoport. * í~ k*. »sk-'KO - \<.'p<'-r » '1 ' k n- ! . -ntn«- ns ? Î % h Η- '-O.k 0 -.-.»rx - η?'- 'k K k íxoporsos jslastsi; R* 6.« R·** mlníkgyik föggssleniöl kkh»:>«vn atíSROt Jslsk vxfy kkkC6 slktk t. 2-í. nîkano!» vajg,··' 01(:¾ íOkOa^ülfesiíí csopmtoMeleot. awlvock opv Ic-ííúHxíís va« szubsxtihs^m. amtk U '.«n vaias/t'-i» a knvvíkíölklkO álló c^opíStbók hsbgóa alom. Síkiro-oí cnop-'-rn cin-sn v»<>ríxí, CÏ- k'P alkoxä v^oport.. Ci-î'ç> » skkulksl -:»>opoîf, CT C" aO-ano»! c«»p->!» <-s Cs i. .»IkîlaxiM'-nO »-χνρηρ; Rîi: os IC1 msudepysk ksgpvtUasSI hîdnnÿn *?05»s-x .ívk'»·». -ssgy CCCP allai i.ä-<. 7 silkaXiXl vafy 11--||:JeiPök: sssalypsk ^cioÄÄyasiiSastfeagptw^^ ax^xly :M vmmimms· ». 'hdops ·;Μ«Ιί^ΐΙ»(ρ^ρΛκ> "«^#««1%- ll-CCkatosiaxöixixt- Q* CP cskls>alkil esopon, £1-11 alksßPil «sapait es; CI-C6 sclksk/sslSoiSl cassp-xi: és \ '«η» H ' -«!' -k C'iy..'- n- >.'f0.. -' .\k»vaa!}«v v-*.»· » -\»;> a ana-víkaf t. \ » ή Cs;-- »agyansî»- -r.wn χ·ί»Ι·χ.-'»kiMdhaK-»-''i» va»; M nvxl ».'inaixä-x'ks». anag> -»/ - Wftvpoßihaa deHsksiSva v:â%ah<R R! h»»k<.igCsi a»p sayy OäiCglbaköiStisäi -;sgy .hidftiRsk'csopi^sk
  2. 3, Λ vegyüli:·? , vagy aarsak gyogyvíVRfxekk'g el íoyadb.»k· vf« vagy N-onuI volrse-socka. gyógy se 1. vágj 2. ägfedVpökkdik dsilkiáJvá kfd, ah«; R: kok; vggy gy skl esdpoit a? ne ly nek dgaiodälisad vsa. sköfsKdtuddsf,; snedy lg vad yfkisgifa a köveikeKöfcfeiä äks esügülthál: halogén .»kSíd, IMíokíI saopdfk cboso ονοροί?.. axsnno eSögüät, k i Cd ;dkü es?5|Ksrk Ckk-OS iáksaxi yvopon. ?·;)!ο ·(.';.·(. ü aikb caegori ev bukoa j-Ci -Cd alksl a κοροη. 4;. ··> vegyül:·? , ysgy sneak gy??yyve?aö;:K-kkg ykygMh&amp;ki sq|g kagyJy-oMd agadnak#®, skögy ax 1,. ahol Λ! és Â" akddkkôô sxydissddiäiailsd esésűit 5, Λ vcgyidci vagy asxask gkôg5:Vi«fks.aatkvg elÉèpdlMô ssysa Vágy N-o:\ki s.ónixa}«'ka. akagy<?>·· *. kgdoypi>sikî!ïa ifekfsilkbirvsfg ahíd s ysvxxa· uploî #' ij sxsskid csogod:
    I afe-1 ! egy esvgefk asneiy k? vsa válasxíoa csögosíbél, a?5:#yg| k®|dyfMl u>· k)> all;
    c b-tö ) (ahol K2a h kis-as a ;d->:noï: gawd. vug y ( ; A.A álks!, €a O'? Akbalkk vagy CM.'" ΑΜχνΙ gs<gMSA jvlvm, slAkyygA opvSösälkäß Vsm sgpfe«gtíft^S% Ävtj: léi vm- vàbssivs s këvslteôkkêl âiid ;:sv|M's;hál: kak-gvn ssosn. hűha»:*! ivágást asass cvogvri €:1ν€δ síkosi:esöfáSíf. i 'MC sakCslki; cs<:|'vaa éa CMk? alkatsál gsöfsark vagy -kC'-ky vagy vavgorKd ;c!vM: Cy. CM Μ"': Η.'1 Μ Μ.'® üfgsösgsisi a jMatéasai feg sast sa t. kMypvmtkskk Ä4-egy v;tgy fevkö vagv tlSkk aMkfe ca->|x;»';: ssssSy s vsifgad sbuH gyilnÇl alMgv a;sa;y CggcMes; vashsaüíualvu labv; kakyM; slosssmib MdtoklI astîparitsi ö -€k aikil MyartAk takkmkü] -C6 stfell MaMMl ya|A ?>. A vvgyasví . vagy usssak gyayysavavascklvg viMadhaC ső|á vs|:y A-östt saákdsaáka, shvgy; sa 5. H:vaygossixiR se átválva vsa. aha; képltst (ab-k) cvagsrs:
    (sN) ννχκ·;;. ;xndy b vais vabw-va vangonbAi, âïxîftlÿii! kvpbüxk (h-1|:j áll:;
    { P Π i abnl V;:·y vagy kenő xayy bbk abiiMö csopöit s cysynrt ahbx gyüstgb: aibVp.. Süggvikrbi syiibkkbbiskslisbbk hálogéö äibbxtbäl.· tabxgbl s inyxn'Aab k i -{. 6· gikbpskpbpylv làdk>b'471-'€b kik il ííkogsistíSj vagy -kr V ΝξΗ :ÍS}K" aV:iporg|k 7, &amp; vagyöfer. vagy aanak gyégyssyssyíekteg yjlbpdkaíó sója vagy N <κχΙ ayármaaáfci, aibgy aa#, igsíiypoístkaakelaalllva. vsa, atel akx|>k| tab·!} sayrlsb syogíjxt:
    I sbs ' l I sssípon. &amp;m«ly b vais válsvm-a <ss?p<>ít!>bL «meiy képletből 4M:
    I b-12 } akal egy vagy keöy vagy s«bh sigillés ssofxxy, a mély à éptxgi: állfaa gj%7lféi alioyy, yméiy faggcde-aH sanhs.assblhak· haksgsa atamans!. barmo! vftispmiiaà i'; - 7'6 u’kg slispgrnyk bumxs-Ci ; -(7a .aksi ííssxxsvbal vagy ysbykliai A vvgyülvi Vagy annak gyagysaaílsaetílsíg albpdtsató Mija vagy N-vvid asámiaPka, akagy m 1. iggxppaaba:nA!gftöi||Va vp> aboi kgplabCs^al j vaaxbskvskporb
    ! sb-1 } Vagaat. anídy ki v;s;· Y.iian/u a vssgxsribÁk ass-cly lappba! {;>·><;} ab:
    ffeáM): Misii vgy vagy keOti vagy isiik metiies sssgieA,: amely s a-ssposi alOIs yyangA atotta, lliggeifegki sanOsaktaailiaté ksksgen ag&amp;nttfót fbőmslt eaeportiak CI·<% aikii c sopor;· ai, indfoaví/l -Co aikii csoportjai vagy •Cy VNYR^iK'" csapom«;.
    0, A vegyuka vagy annak gyögykgAékKkklög eOogadbaA ágin vagy Nősül s/ancaAkp. aboy> .·· f. igégygödíMn sfytlsMvy vak, a|ió| képiéi pikAVsAiiM vsopóra
    { akvl I csoport atnsdy ki van válásivá csop-OrŰxkL amdyeî kópiáikéi inA Π áll:
    I akid egy vagy .kettő yagÿ tőkli okodon oonors, pane; y »a gsOpoyi: kHíag ygybMdgt gtksska, bpiogco saoospsk hkirosd csoportúd. (Ί·( 6 ;dk.b csdpixMal, tndroxcy · A ft ;dkd i:a<.gxvgal vagy : n;; R:”;F csoportú
  3. 10, Λ vegyütet < vsgy ägä?gk gvOgysaesäsaöltleg alkípiáhsaé ső|a vagy N-»xict saàfîiisslkax ahogy a 0.. sgéö.ypöii:tfee.n.aiaikiM ! va van, Maxi .képiéi tab“ i s ssamati e gapari :
    ( afo-1 ) egy kéyiíX .(b 431 waarMi osaixa'k
    :f: Mai slsi! agy vsgv ke-sô yagy ;4bk sptjléd caop-on. imbdy a exigxxî: 3475% gyibfiisî a&amp;dijik Jlggbiteäl xgxbksbkgdlyäid halogáa akpikaxl Idlfcasii! xKyxxrxak (/lx x 4¾ ykogoitlsl,. bk!dayi--Cl|-(34 îàka oabporbal xàgy -0:s-N{R:ï'.4<:: bsbpbtMiL 3 b Λ vagyiH-x .. vagy ssxaäk pyèpyaxaaïsaailkg -Xíogadha-o síp vagy N-οχ kl sx-nv-aaéka. ahogy ax 1. ígéssygoxiísa» dsissdälva van. aboi a M-pkb kb· ! I »gadad asxpxat:
    líMii axopsxk axaby kl vaa vslasg;va as»p«r4x>k amsiy kdfbabksl ik-3k; all:
    (fc-38 ) ;\!;o <-gy -.-«gy kcxb vagy íodh asóbíán csop-ark apsly a <:xoporî aklas ipkypslkogx. 4;gg<.-4orxd :-oyb«xOiyóHss;4g kalogóa a;<;nsxab bi4o:>x4 covaxanai. k l-Cb alkd c\oy>xaa;. kalrxxoCl-Ck alkü wgxx'ita; vagy -p ' -Nbípk " cxopoxk-ik- ko Âa k agàsiygoxi x-ox-xu vggyiPb axi«ly kl xatï: yáiaxaíxa à k;:o<xkíx-x> vcgybî-xck köbd: kl) b-ppdsMbdybbM-'bbfnîX'TpykkpIbSkS^dpdrb-ibb^ ïl)ssiïi iíM-^^ö^í^ísií.íSö|^4·^ S'^|p:iïÎmijâÎ"îS'--3Î 3 ÍÍ^í5tVj. (ο) k-:(:o,S-biklór(aíXS}-vklxbxa'kii:[2i.4;batns5ebliikk3,4xi:«ga(adfOixokÍ3aa!kxk-íÍj saxao; - 33 dk:k!x>kiaÎXîsd<5|4iS':ëjgbkaiàin'2(lll)"OXi (3): 3 “(2^ik^’dîlç^-çskï^iÎiÎ 'krí'íiyií3:-lo -{í t;. ! ; S - ;í riiköéíy|-, 1 oií1®iâdii<|k<3i^>ki£îÿ^ i:í>«íy-íkkiSkíaáí>yy|^3 ;;4 -^ dikxbopirsxkkp.y -xpnxvkíbikb IΗ)-;χ·: í4í 3--(:2>4-4;kkK|>;íkkx-k-X}·4-iaoüo·'?-f y 1,-!.bxsoxxi-i,3<3gpgXrahldro(gekdxbp b-· 71] apxoi-iSí-sIjiíiriísiiilö^SÍ I î (Sí 3 ο{1ώ.;ΐΐ:'^ϊ;^Ι:^Γ^ΐϊ yid'iä y0 (nöx o ~ (Ç1,3 i-o otílíTiií í iloio äSyblciri ϊγ· ( Idkssvöäyafe^ - S oj IJss ssa iiîîTsiolÎ .4- (b) 342pdsy4gpsdi'-7'C[2'pPa4Üa;ndBp-3p4i]yfePlf4pefp4 3v4»d PdKpbPdet [4, S-4]pwlmM»a2|.1 Μ)-οχ· (3| 3433--4444.:.444-?· ((3-.(doxakkm-xx-V- 5i;! <4η;<·:;!-2.3-4(hklitoIH-344(4--3a; paino(-4-- BViXK:-3 A -dd;xkopin:ni4;4"t.5-ii psin-xiio 2( ; H go» k s Η . v ) - St' ϊ* ' i '< V. ' < >t V I* »f* X Li Kt'*' *· ' Ns.n\ Unh 'Wv! ν'- 4.4 dda 5 . pi'mvi.'Í4vS\íiín«<n:*\hn GUT' <. '' «'<#> ι4 »kn ' V '' *>\íV ' * v »'in ' U didf» \ h ''>'"* djUHhnníiTRnddl-í·.''-d jpiî'Hîndin- 4( i 1 i KHii (!.(;) -¾ i^:^#^<Ís_ÍIuor tííílíl ! ΐϊίί:33Εϊ0Ϊ:;? ^-: 11:¾ «-iSsStti 1:¾ :s#- tÍ:K:^;í‘íí ísisSíx^iiiö |δί>ϊίί·ί ' djhidt^pn'imkäe;4,S-'d]pKH5isdm'-2iiHi'öi!:. dâhK|}:i>{Mi'iïîâHkï| 4 Λ-ci IpimüxUcy'ïiï linon; ϊ VI) -ifi-iiiîd*rfçtïii>-7-H dM#^maiîiei[4.5-4|js>inmidW'2{ \ H Hw: J'> * . ' <' disk» k î J> ^ U t-i nd v \»v\î}s I nais. ' 5 >ntn «d.....k, ' '(. ?> ' Î s 1 -nnnüt î -nH'id - k'i'djhult^irimsd^H 4- d»fmmsdns- .:< dh-i'S ΐ 14ï ?-{it(kdskfek;f5;!)-4-.«sù^>··?· i(;><4ii· Lí 3,4-k4tah>idroiáokitH>U«-<>»i1ja*n«Kd 0,4- ;#&amp;^^ΐή«$κΪο(4Λdipirroridi»-2i 1S l>~Ois; 05} '>·( ’» dk o> onkl 4 in i \ ' d' «05» i ' ** dA'su io s ,i, k d's s ,oi » I <k,háir<fdyknido$4d^HÍ)p!ííÍ5ddin-2:; ä H koty {Ibi ' O ti dud 'rkxnb ' (>' -reu η«ηη» V ' »» hid'd II Η'ύη * v -' 'dH 1 dihKSk'yn.yiods' d * oiyr»« »»ko ΉΙΠ <.«) U?1 3'(?>6-<íikíwfra9^7-{f?-<<hn»co»tó«íK'V5^".N^íri^Ns#fc2^ffi^:v4íiÉÉs^ií#:. dthiJrgnrorod-oí-i.4 »> j-non-idínGi IB>-on; í i S) 's -i ;: io-OkOdViniMncnino·'; ·(( ' ·oKuik2 3.4..4-Hdraiinlavl H-4-beasaKep&amp;t-'? -silannooj- 4.4-<!iiii;!ïî!pifîîîîido|4.>-d)pif?î»:<àin''3{ ÎHHîï:. (IHí ». i λ \ ·> »o'I ' st> .is msîihi' ' i's t> SK' lin 'íisikíIm'.í-d‘3í?Hn«M-·.- !i 'iiV-5.4-dH'iJ'.»ii'5'.Hi! 00. k^-d^Hrm-id-loO ki; .-η. «*><> ;. -.je.η' M-vfontSil·' '.' sî ';.n,ch\l· ' \Λΐη>·>ί»ο»' űkn 'tn»>i - (- »' sk\l. ;k'o.dn- un no- » í .hb'sdioy sHwj'S 4 '- i^-inovsdoWtii»» Oíí, vags· ununk gydgjüÂeyëszetik.e u;:c>gadhniú adni v&amp;sy N-oxxi &amp;í'iiíHíasf(C3 4d. GacsayscOyésaotl fekípTOíIil. auîiîiy iari&amp;Im&amp;íW» a;·: eiö:ab igés-yposHo!·: baniiOySKg s^éknk: acd’suk'í ».0>c .;Ji xA CsSA'i'Css'i.i'if.^ . .vs.il 'S>s \ - .\.^<. \ .'\idi.i Î'îàï'i3s4'~ í ' *"" 'rv '4 t'î s gy^gy.v.dr^x^etifeg ehb^dhuK' k^rdiygdt vsgy· hsgikst: 14 Kvnibösk id dgyidcjsi cikdlómte« \s>gy «gy««b «i&amp;m adagoIiiSiH. aníeiy k>i aj: MJ?; dgès^soafek- #gf4ik4ei: «»Ä :ρ'<·η>'χ?·<ί?-^·?8ί^ι ellogsHlIidSd rk-sás vagy 4<-oxsá x?:ánr.aack;ik c:; ih) rákílks«^ «π, c.aiíis Ki \an va':as?í\a a K<->vcàeadl:bôI áík> cxopdnbok ránddíirrJ adiík'.--:i> N*m'k. !'ákvik-!H\-i oni;íiHd;:'.(xdik:k., v&amp;kdîesçs áx»tb«>dbimf»k. abvéayekből s?.arma2.* .vs««?;.. sálsilldkdy^ iyMÍfedyS üSä&amp;Ä^Äk®% - ra^iíe^ iU%i?Äi&amp;· - hd íHvíK » .!ii h il's v'muest'k. t hoj\ d'í k. no nyai -skví jífeddNdsjk:: cs s«w ;.ikc>.»euc> >>a.vcH. \ agy annak g y <'igysadfé>>2ítiíeg eifc-gadhaäd adja vagy tSalaäd. ahol , nskdk·;*«·» ,kkik*b Ss«*«k núri.>g«ním* N-oxkl , c%lötssa:|gsft;s!Í ífexsfemki iííííob^oi?«!. kas'bogtnss, ímoísps, s-anÉrnysün. «smu^a. iemosolosmdps: eaímgstíig á s\!í>vk05i>'v At»íiní*'Ubi»l«í4· n os' oí y\ j .«m -gv sd. :¾ s ·, ψ. w«.i. ' , sm 'tj . 5«w-:{|Vr «i'íOUábm. S-l. gc-immabm.. Oudarabn; Ή gCXX'i>0'Ob baxk:"i>: :X. a rákkílpg« §»í;ifei0Ö.kíaí5^· «cíkíQmykm Oy d&amp;Kámfekan,, áaua^Mdxí, Äxxsfdööst&amp;til% i:d-’á»'ydík gbptóbíáPík íPb^PN %'·» «íd&amp;rdskiá, igimpöfekítt,. «§dmbsdss, a^Kágkks síkm&amp;«5«sy ÚknsbK.'k:· ígokníoy. ó? VSÉilíbivsís, a: sdwsyh&amp;? sxâmaaê kkdteks 4&amp;α0ί vkiOfssiss, yidblg^ky kkPxbisg setppsÄ piai». dofesíMgk i^bta ssk 4» ^teibfe :a íikklkEíg« dfebkskSidâpks wgxSkïek cisplaiígi ksskkipfsigg ηΛρΜ% Is oxalp&amp;jk; a î-âlxlkîîæs oasspdls«x;ss s?arm3Ä«tK. M$á«ÍÉ*» «»pfeekk ts gSipkkbkiSsi:; iiX k . v. - k? < k ' ' « O t Îâf ^ w ' o T 'ín b s : n*»aok$««$bk aPfeisk eefessassh, ímaázmak, ÄsMab, ateksamák es ÄiuKddäb: a:o: m?effcro«<>k dírrkrsm ö, bbpkï«?s «dd. isnerkros; u-2h.. iatsfer^äm«,|k itHes-kron pa. <>. mmtMé&amp; y-îi-k a: Böiég&amp;t váMisg iSodöskik ks?eÄk taftnae,- sösss&amp;ms. |sk?sbassl, v&amp;gr^ámm, sás a más rákeiknox s/osok nkRákssfc. Í:'8r|pr^m^:v- -ifeiksíiSa^íiií ihsíd^si^i^s^íív a*Htms;«iw, nwíwin. skfa^. dnb*po«UbÄ a»asKO*«k exeroesta«. Iwcaiuramid. knpmrdm. Buimmb. $1) vêtira*· pegapíanífe ocuattnum. dttriteukM #§*«&amp;,. aÍ4«d^kp 4% &amp;φΦ®*Μ , bonca^nub. cap?c«&amp;b*n. « gosm-Sm í * -.4¾ Í--12; Ütmeim miM %«tföM -*a^ «ássák -$%p4fM&amp; f óns vagy N'-oxkí x/kmâaæka kfeasáíáxm tórágiábsa !é A* M|; i£-èî«yy:>x>=îïok bánndyske sxp:p vcgywki vagy 8«nak gybgysiænkxebkg etmgadbmó Sáp vagy N-gxkI Ngsni-íaéka feíJiax?aníasrs mk koaak'-da'a |:í, :&amp;£: KÎ&amp; p&amp;opssísá bsmdyfe s^nati: yogvite vagy agßsk gyísgyxaerexKsRílög síRsgsckísub :Si|a vagy Hsosdd sPmkPfa vagy: * !4. igpyjmd ssemîs ksmbmskk isdMssspsss komkasoofea« sögáncí-ágiáxííí. a, m..mwm&amp;:^rnm^mdmm> »k^Γ dbikfsSdsiSä.
HUE08777358A 2007-06-15 2008-06-12 Bicikloanilin származék HUE032403T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007159217 2007-06-15
US96591807P 2007-08-23 2007-08-23

Publications (1)

Publication Number Publication Date
HUE032403T2 true HUE032403T2 (hu) 2017-09-28

Family

ID=40129803

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08777358A HUE032403T2 (hu) 2007-06-15 2008-06-12 Bicikloanilin származék

Country Status (22)

Country Link
US (1) US8436004B2 (hu)
EP (1) EP2168966B1 (hu)
JP (1) JP5129812B2 (hu)
KR (1) KR20100024932A (hu)
CN (1) CN101784551A (hu)
AU (1) AU2008262837B2 (hu)
CA (1) CA2689429C (hu)
CY (1) CY1118448T1 (hu)
DK (1) DK2168966T3 (hu)
ES (1) ES2608940T3 (hu)
HR (1) HRP20161536T1 (hu)
HU (1) HUE032403T2 (hu)
IL (1) IL202262A0 (hu)
LT (1) LT2168966T (hu)
MX (1) MX2009013728A (hu)
NZ (1) NZ581936A (hu)
PL (1) PL2168966T3 (hu)
PT (1) PT2168966T (hu)
RU (1) RU2010101052A (hu)
SI (1) SI2168966T1 (hu)
WO (1) WO2008153207A1 (hu)
ZA (1) ZA200908298B (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2719376A1 (en) * 2008-04-07 2009-10-15 Gilead Sciences, Inc. 2h-benzo[b][1,4]oxazin-3(4h)-one derivatives for use as stearoyl coa desaturase inhibitors
ES2430053T3 (es) * 2008-06-12 2013-11-18 Merck Sharp & Dohme Corp. Procedimiento para producir derivados de bicicloanilina
EP2376493B1 (en) 2008-12-12 2016-10-05 Msd K.K. Dihydropyrimidopyrimidine derivative
CA2745959A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
JP2012518598A (ja) * 2009-02-25 2012-08-16 Ｍｓｄ株式会社 ピリミドピリミドインダゾール誘導体
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2013013031A1 (en) 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
EP2755482B1 (en) 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combination of mk-1775 and mk-8776 for treating cancer
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
CN103113311A (zh) * 2012-07-19 2013-05-22 南京邮电大学 一类2-芳基喹唑啉或2-杂环芳基喹唑啉衍生物及其制备方法
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
JP6290237B2 (ja) 2012-11-28 2018-03-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための組成物および方法
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MY181020A (en) 2013-03-15 2020-12-16 Sanofi Sa Heteroaryl compounds and uses thereof
BR112015022191A8 (pt) 2013-03-15 2018-01-23 Celgene Avilomics Res Inc compostos heteroarila e usos dos mesmos
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN109776525B (zh) 2013-04-19 2022-01-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
CN104725333A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种新的氮杂环庚烷衍生物的制备方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
WO2017031116A1 (en) * 2015-08-18 2017-02-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of ku70/80 and uses thereof
EP3380194B1 (en) * 2015-11-24 2023-11-01 Indiana University Research & Technology Corporation Composition for blocking angiogenesis
SI3558997T1 (sl) 2016-12-20 2021-07-30 Astrazeneca Ab Spojine amino-triazolopiridina in njihova uporaba v zdravljenju raka
JP2020512977A (ja) 2017-03-31 2020-04-30 シアトル ジェネティックス， インコーポレイテッド Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3694509A4 (en) * 2017-10-09 2021-07-14 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN109810111B (zh) * 2017-11-20 2023-10-27 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
BR112020022392A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020210377A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210383A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
JP2022526831A (ja) 2019-04-09 2022-05-26 ニューベイション・バイオ・インコーポレイテッド ヘテロ環式化合物およびその使用
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
IL291901A (en) 2019-10-14 2022-06-01 Incyte Corp Bicyclyl heterocycles as fgr suppressors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022007609A2 (pt) 2019-10-25 2022-07-19 Astrazeneca Ab Métodos para tratar o câncer
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US20240182447A1 (en) * 2021-02-19 2024-06-06 Wigen Biomedicine Technology (shanghai) Co., Ltd. Fused ring compound as wee-1 inhibitor
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4329815A1 (en) 2021-04-29 2024-03-06 Novartis AG Deubiquitinase-targeting chimeras and related methods
AU2022265032A1 (en) * 2021-04-30 2023-11-16 Wigen Biomedicine Technology (shanghai) Co., Ltd. Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023170065A1 (en) 2022-03-07 2023-09-14 Debiopharm International S.A. Methods of treating small cell lung cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69939168D1 (de) * 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung
HUP0300136A2 (en) * 2000-03-06 2003-05-28 Warner Lambert Co 5-alkylpyrido [2,3-d]pyrimidines tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US20060063786A1 (en) * 2002-11-15 2006-03-23 Tormo I Blasco Jordi Fungicidal mixtures for controlling rice pathogens
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
TW200530235A (en) * 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
FR2873118B1 (fr) * 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US7550589B2 (en) * 2004-09-21 2009-06-23 Hoffman-La Roche Inc. 6-(2-alkyl-phenyl)-pyrido[2,3-D]pyrimidines useful as protein kinase inhibitors
CN101227857B (zh) 2005-06-29 2011-10-19 电脑医师有限公司 具有导电桥的传感器组件
DE602007008837D1 (de) 2006-02-14 2010-10-14 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine

Also Published As

Publication number Publication date
SI2168966T1 (sl) 2017-03-31
HRP20161536T1 (hr) 2016-12-30
ZA200908298B (en) 2010-08-25
IL202262A0 (en) 2010-06-16
CN101784551A (zh) 2010-07-21
EP2168966A4 (en) 2011-02-16
US20110135601A1 (en) 2011-06-09
CA2689429A1 (en) 2008-12-18
CA2689429C (en) 2012-08-21
PL2168966T3 (pl) 2017-06-30
LT2168966T (lt) 2017-01-10
RU2010101052A (ru) 2011-07-20
EP2168966A1 (en) 2010-03-31
CY1118448T1 (el) 2017-06-28
JP5129812B2 (ja) 2013-01-30
AU2008262837B2 (en) 2013-05-23
NZ581936A (en) 2011-08-26
KR20100024932A (ko) 2010-03-08
DK2168966T3 (en) 2017-01-23
PT2168966T (pt) 2017-01-02
MX2009013728A (es) 2010-01-25
ES2608940T3 (es) 2017-04-17
JPWO2008153207A1 (ja) 2010-08-26
EP2168966B1 (en) 2016-09-28
US8436004B2 (en) 2013-05-07
AU2008262837A1 (en) 2008-12-18
WO2008153207A1 (ja) 2008-12-18

Similar Documents

Publication Publication Date Title
DK2168966T3 (en) BICYCLOANILIN DERIVATIVES
EP2213673B1 (en) Pyridone-substituted-dihydropyrazolopyrimidinone derivative
EP2376493B1 (en) Dihydropyrimidopyrimidine derivative
US8575179B2 (en) Dihydropyrazolopyrimidinone derivatives
TWI409262B (zh) 二氫吡唑并嘧啶酮衍生物
EP2303885B1 (en) Process for producing bicycloaniline derivatives
JP5411847B2 (ja) Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
US8288396B2 (en) Pyrimidopyrimidoindazole derivative